Sur8, a determinant protein in colorectal cancer tumor progression

Resumen del trabajo presentado en el 43rd Annual Meeting of the SEBBM, celebrado en Barcelona (España) del 19 al 21 de julio de 2021.Colorectal cancer (CRC) has the highest incidence rate in the Spanish population. The most important challenge consists on the discovery of efficient disease treatments, due to high mortality rates in highly developed stages. Sur8 is a scaffold protein that positively modulates ERK signaling pathway, which has a major role in the progression and metastasis in colorectal cancer. The main goals of our research are to determine the role that Sur8 plays in the development and progression of CRC and to analyze its possible therapeutic potential. For this purpose, our group has developed an inducible conditional mouse model msur8f/fVillinCreERT2. In order to determine Sur8 action in the colonic tissue, we have developed organoids from the colon epithelium of healthy mice and have analyzed gene expression pattern by an RNAseq approach. Sur8 KO affects oncogenic CRC transcription factors expression, as well as the modulation of some Wnt pathway regulators. In regard to miRNA data, we have observed deregulation of miRNAs related to CRC in Sur8 KO organoids. To determine the role that Sur8 plays in the development and progression of CRC, we have subjected our inducible conditional mice to chemical carcinogenesis and we have observed that Sur8 KO males display less and smaller tumors and do not present any adenocarcinoma. In addition, we have carried out Sur8 silencing in human CRC cell lines by infection with constitutive shRNA lentiviruses. We have observed that Sur8 silencing produces decreases of cell tumor proliferation, and reduction of p-ERK levels. Finally, we are evaluating the effects of putative therapeutic agents against Sur8 in human CRC cell lines. Concretely, we are testing Celastrol, which has been described that binds and blocks the action of Sur8 in vitro. We have observed that Celastrol treatment diminishes the cell tumor proliferation in this model. Altogether, our results indicate that Sur8 may have a determinant role in CRC progression and that Sur8 could be a potential molecular target for the design of novel strategies against CRC

Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer

Sporadic colorectal cancer (CRC) insurgence and progression depend on the activation of Wnt/β-catenin signaling. Dickkopf (DKK)-1 is an extracellular inhibitor of Wnt/β-catenin signaling that also has undefined β-catenin-independent actions. Here we report for the first time that a proportion of DKK-1 locates within the nucleus of healthy small intestine and colon mucosa, and of CRC cells at specific chromatin sites of active transcription. Moreover, we show that DKK-1 regulates several cancer-related genes including the cancer stem cell marker aldehyde dehydrogenase 1A1 (ALDH1A1) and Ral-binding protein 1-associated Eps domain-containing 2 (REPS2), which are involved in detoxification of chemotherapeutic agents. Nuclear DKK-1 expression is lost along CRC progression; however, it remains high in a subset (15%) of CRC patients (n = 699) and associates with decreased progression-free survival (PFS) after chemotherapy administration and overall survival (OS) [adjusted HR, 1.65; 95% confidence interval (CI), 1.23-2.21; P = 0.002)]. Overexpression of ALDH1A1 and REPS2 associates with nuclear DKK-1 expression in tumors and correlates with decreased OS (P = 0.001 and 0.014) and PFS. In summary, our findings demonstrate a novel location of DKK-1 within the cell nucleus and support a role of nuclear DKK-1 as a predictive biomarker of chemoresistance in colorectal cancer

The ERA-EDTA Registry Annual Report 2018 : A summary

Funding Information: The ERA-EDTA Registry is funded by the ERA-EDTA. This article was written by A.K. et al. on behalf of the ERA-EDTA Registry, which is an official body of the ERA-EDTA. In addition, V.S.S. reports grants from ERA-EDTA, during the conduct of the study; S.B. reports personal fees from Astra Zeneca, outside the submitted work; P.F. reports personal fees from Baxter, outside the submitted work; and K.J.J. reports grants from ERA-EDTA, during the conduct of the study. Publisher Copyright: © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.Background. The European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry collects data on kidney replacement therapy (KRT) via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article summarizes the 2018 ERA-EDTA Registry Annual Report, and describes the epidemiology of KRT for kidney failure in 34 countries. Methods. Individual patient data on patients undergoing KRT in 2018 were provided by 34 national or regional renal registries and aggregated data by 17 registries. The incidence and prevalence of KRT, the kidney transplantation activity and the survival probabilities of these patients were calculated. Results. In 2018, the ERA-EDTA Registry covered a general population of 636 million people. Overall, the incidence of KRT for kidney failure was 129 per million population (p.m.p.), 62% of patients were men, 51% were 65 years of age and 20% had diabetes mellitus as cause of kidney failure. Treatment modality at the onset of KRT was haemodialysis (HD) for 84%, peritoneal dialysis (PD) for 11% and pre-emptive kidney transplantation for 5% of patients. On 31 December 2018, the prevalence of KRT was 897 p.m.p., with 57% of patients on HD, 5% on PD and 38% living with a kidney transplant. The transplant rate in 2018 was 35 p.m.p.: 68% received a kidney from a deceased donor, 30% from a living donor and for 2% the donor source was unknown. For patients commencing dialysis during 2009-13, the unadjusted 5-year survival probability was 42.6%. For patients receiving a kidney transplant within this period, the unadjusted 5-year survival probability was 86.6% for recipients of deceased donor grafts and 93.9% for recipients of living donor grafts.Peer reviewe

Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.

Background: Data on durability of first-line antiretroviral therapy (ART) in children with human immunodeficiency virus (HIV) are limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand. Methods: Children aged <18 years initiating combination ART (≥2 nucleoside reverse transcriptase inhibitors [NRTIs] plus nonnucleoside reverse transcriptase inhibitor [NNRTI] or boosted protease inhibitor [PI]) were included. Switch to second-line was defined as (i) change across drug class (PI to NNRTI or vice versa) or within PI class plus change of ≥1 NRTI; (ii) change from single to dual PI; or (iii) addition of a new drug class. Cumulative incidence of switch was calculated with death and loss to follow-up as competing risks. Results: Of 3668 children included, median age at ART initiation was 6.1 (interquartile range (IQR), 1.7-10.5) years. Initial regimens were 32% PI based, 34% nevirapine (NVP) based, and 33% efavirenz based. Median duration of follow-up was 5.4 (IQR, 2.9-8.3) years. Cumulative incidence of switch at 5 years was 21% (95% confidence interval, 20%-23%), with significant regional variations. Median time to switch was 30 (IQR, 16-58) months; two-thirds of switches were related to treatment failure. In multivariable analysis, older age, severe immunosuppression and higher viral load (VL) at ART start, and NVP-based initial regimens were associated with increased risk of switch. Conclusions: One in 5 children switched to a second-line regimen by 5 years of ART, with two-thirds failure related. Advanced HIV, older age, and NVP-based regimens were associated with increased risk of switch

PGA1-induced apoptosis involves specific activation of H-Ras and N-Ras in cellular endomembranes

B Anta et al.The cyclopentenone prostaglandin A(1) (PGA(1)) is an inducer of cell death in cancer cells. However, the mechanism that initiates this cytotoxic response remains elusive. Here we report that PGA(1) triggers apoptosis by a process that entails the specific activation of H-and N-Ras isoforms, leading to caspase activation. Cells without H- and N-Ras did not undergo apoptosis upon PGA(1) treatment; in these cells, the cellular demise was rescued by overexpression of either H-Ras or N-Ras. Consistently, the mutant H-Ras-C118-S, defective for binding PGA(1), did not produce cell death. Molecular analysis revealed a key role for the RAF-MEK-ERK signaling pathway in the apoptotic process through the induction of calpain activity and caspase-12 cleavage. We propose that PGA(1) evokes a specific physiological cell death program, through H- and N-Ras, but not K-Ras, activation at endomembranes. Our results highlight a novel mechanism that may be of potential interest for tumor treatment.APR, TG, and LMD were recipients of fellowships from the Comunidad de Madrid (APR), Ministerio de Educación y Ciencia (TG), and FIS-BEFI (LMD). Grant support was awarded to JMRC from Fondo de Investigaciones Sanitarias-Intrasalud (PI09/0562 and PI13/00703) and the Spanish Association Against Cancer. JLO received grants from the Fondo de Investigaciones Sanitarias (CP07/00141 and PI10/00815). AM received grants from Ministerio de Economía y Competitividad of Spain-Fondo Europeo de Desarrollo Regional (FEDER) to AM (SAF2013-43468-R), Comunidad de Madrid to AM (S2010/BMD-2344 Colomics2) and Instituto de Salud Carlos III-FEDER. JMS received grants from the Fondo de Investigaciones Sanitarias (PI070356) and ‘Ayuda Intramural de Incorporación al CSIC'. ES, AM, JMRC, and PC, respectively, received Grants RD06/0020/0000 and RD12/0036/0001, RD06/0020/0003 and RD12/0036/0021, and RD06/0020/0105 and RD12/0036/0033 from Instituto de San Carlos III-RETIC (Red Temática de Investigación Cooperativa en Cáncer).Peer Reviewe

THE FORENSIC INTERVIEW: OBTAINING COGNITIVE INDICIA IN CHILDREN WHO ARE THE ALLEGED VICTIMS OF SEXUAL ABUSE

The characteristics surrounding child sexual abuse (CSA), which is committed in secret without witnesses or corroborating physical evidence, make it difficult to prosecute. The analysis and assessment of the cognitive indicia (memory trace) thus becomes the primary documentary evidence on which the judge relies. The forensic interview is the instrument by which the forensic psychologist obtains the cognitive indicia for further analysis and assessment with regards to credibility. The present article warns of the potential interviewer biases and procedural errors that can contaminate the child’s narrative production, and proposes a design for the forensic interview process that aims to facilitate the evaluator’s task and minimize the potential biases. The need is emphasized for the evaluator to have knowledge and specialized training in this technique

LA ENTREVISTA FORENSE: OBTENCIÓN DEL INDICIO COGNITIVO EN MENORES PRESUNTAS VÍCTIMAS DE ABUSO SEXUAL INFANTIL

Las características que rodean a los delitos de abuso sexual infantil (ASI), puesto que muchos se cometen en la clandestinidad, sin testigos y sin evidencias físicas que los corroboren, dificultan el enjuiciamiento de los mismos. El análisis y valoración del indicio cognitivo (huella de memoria) se convierte así en el principal medio de prueba con el que cuenta el juez. La entrevista forense es el instrumento mediante el cual el perito psicólogo obtiene este indicio cognitivo para su posterior análisis y valoración en términos de credibilidad. En el presente artículo se alerta sobre los posibles sesgos en el entrevistador y errores procedimentales que pueden contaminar la obtención del relato del menor, y se propone un diseño del proceso de entrevista forense con el objetivo de facilitar la labor pericial y minimizar esos posibles sesgos. Se hace hincapié en la necesidad de que el evaluador cuente con formación y entrenamiento especializado en esta técnica

AliQAn, Spanish QA system at multilingual QA@CLEF-2008

Comunicación presentada en Cross-Language Evaluation Forum (CLEF 2008), Aarhus, Denmark, September 17-19, 2008.In QA@CLEF 2008, we participate in monolingual (Spanish) and multilingual (English - Spanish) tasks. Specifically, in this paper, we will tackle with the English - Spanish QA task. In this edition we will deal with two main problems: an heterogeneous document collection (news articles and Wikipedia) and a large number of topic-related questions, which make somewhat difficult our participation. We want to highlight in the translation module in our system two possible mechanisms: one based on logic forms, and the other, on machine translation techniques. In addition, it has also been used a system of anaphora resolution that it is described below and a QA System, AliQAn (also used this year in the monolingual task)

Dissecting the protective role of vitamin D3 on colon cancer: new targets from protein degradation machinery

Trabajo presentado al 21st Meeting of the European Association for Cancer Research celebrado del 25 al 30 de Junio de 2011 en Bruselas (Bélgica).The work in authors laboratories is supported by the Ministerio de Ciencia e Innovación of Spain (SAF2007-60341, ISCIII-RETIC RD06/0020/0009 and Rd06/0020/0020) and Comunidad de Madrid (S-GEN-0266/2006).Peer reviewe

Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer

Colorectal cancer is a major cause of cancer death worldwide. A number of key oncogenes and tumor suppressor genes have been proposed to drive progression from healthy colonic epithelia to malignant tumors, including members of the Wnt/Β-catenin pathway. Recently, CpG island promoter hypermethylation was shown to cause inactivation of two extracellular Wnt inhibitors in colon cancer: secreted frizzled-related proteins (sFRPs) and Wnt inhibitory factor-1 (WIF-1). Here, we show for the first time that another extracellular Wnt inhibitor, the DICKKOPF-1 (DKK-1) gene, is transcriptionally silenced by CpG island promoter hypermethylation in colon cancer cell lines (n=9), whereas treatment with the DNA-demethylating agent 5-aza-2-deoxycytidine restored DKK-1 expression. Restoration of DKK-1 function in non-expressing cells bearing a truncated APC (Adenomatous Polyposis Coli) gene had no effect on Β-catenin/T-cell factor-dependent transcription, but induced tumor suppressor-like features such as reduced colony formation density and tumor growth inhibition in nude mice. These results suggest additional functions for DKK-1 other than inhibiting canonical Wnt signaling. In primary colorectal tumors, DKK-1 was found hypermethylated in 17% (nine of 54) of cases. Furthermore, while for both SFRP-1 and WIF-1 methylation-associated silencing occurred across the whole spectrum of colorectal tumorigenesis, DKK-1 promoter was selectively hypermethylated in advanced colorectal neoplasms (Duke's C and D tumors). © 2006 Nature Publishing Group All rights reserved.Grant support: Ministerio de Educación y Ciencia (SAF2004-01015) of Spain, Fundación de Investigación Médica Mutua Madrileña.Peer Reviewe